

Case report: emergency treatment of near-fatal acute asthma

Dario Lo Cigno, Federico Vischia, Antonio Sechi

SC McCAU e PS, Ospedale Torino Nord Emergenza San Giovanni Bosco, Torino

SINTESI

L'asma bronchiale è una malattia respiratoria cronica caratterizzata da sintomi respiratori di gravità variabile che possono condurre all'insufficienza respiratoria. La NIV è una metodica di supporto respiratorio utilizzata da anni con successo nella BPCO riacutizzata. Tuttavia,

il suo uso non è ancora ben definito nelle riacutizzazioni di asma bronchiale. In questo articolo presentiamo la nostra esperienza di un caso di riacutizzazione asmatica quasi-fatale trattata con successo in DEA mediante NIV, ed esaminiamo le evidenze scientifiche al riguardo.

A 43-years old male was admitted to our emergency department complaining of severe dyspnea. He was assigned red code and was admitted directly in shock room. The patient had history of asthma (but he used rarely bronchodilators) and he was a drug addict.

The patient was conscious but restless, he was unable to lie down, showed signs of respiratory distress with accessory muscle use, he was unable to speak just a single word. Respiratory sounds were diminished on both lungs with severe diffuse and bilateral wheezing. There were no other significative findings to the physical examination. Vital signs were as follows: arterial pressure 145/80 mmHg, heart rate 140 bpm, SpO₂ 70% in air. T 36,8°C, respiratory rate 40/min.

Promptly, O₂ with reservoir mask was administered; a central venous line was placed in femoral vein because periferal veins were not available. The BGA showed pH 7.14 pCO₂ 77 mmHg, pO₂ 44.2 mmHg HCO₃ 28.4 mEq/l, lactate 2.8 mg/dl.

The patient was administered nebulized salbutamol, iv metilprednisolone, iv aminophilline, nebulized and im epinephrine, iv magnesium sulphate. Because of the severe respiratory distress and the acute respiratory acidosis, we started also noninvasive ventilation by means of a Draeger Evita 4 ventilator with a facial mask setted as follows: PEEP 0 cmH₂O (ZEEP) + ASB 8 cmH₂O, FiO₂ 100%. The patient well tolerated noninvasive ventilation. A chest X-ray showed bilateral lung inflation without pulmonary thickening or pleural effusion; cardiovascular profile was normal. (Figure 1).

Blood tests showed slightly elevated neutrophil count (WBC 16730/mm³) while C-reactive protein was normal (<0,5 mg/

dl). After 30 minutes of NIV another BGA was performed: pH 7.22, pCO₂ 66 mmHg pO₂ 453 mmHg HCO₃ 27.8 mEq/l. Clinically, the patient showed less wheezing and vitals signs were also improving: SpO₂ 100% during NIV with FiO₂ 1.0, HR 120 bpm R, PA 130/75 mmHg RR 28/min. So, we continued to ventilate the patient as described, reducing FiO₂ from 1.0 to 0.5 because of the excellent pO₂.

After 3 hours of NIV BGA was further improved (pH 7.37, pCO₂ 45 mmHg, pO₂ 156 mmHg, HCO₃ 25.4); the patient was therefore transferred in medical ward, where he was administered only O₂-therapy with nasal cannula, bronchodilators and steroids. He did not need ventilation anymore, and he was discharged the sixth day after admission.

Noninvasive ventilation is an effective respiratory support technique, mainly in respiratory insufficiency due to COPD




Fig. 1 - The patients' Chest x-Ray showing lung inflation.

exacerbations. There is increasing evidence that in patient with COPD exacerbation NIV improves blood gas tests while reducing mortality, respiratory workload, and endotracheal intubation needs^{1,3,4,5,6}.

Asthma is an inflammatory disease affecting small airways associated with airway hyperresponsiveness, reversible airflow limitation, and respiratory symptoms variable from dyspnea to status asthmaticus². Asthma shares with BPCO some pathophysiologic features like bronchial airflow limitation, increased respiratory workload and increased residual functional capacity, due to air trapping². However, in asthma these features are mostly reversible with bronchodilators, while in COPD they are not².

Another difference between asthma and COPD is that in latter the airway obstructed are the distal, smallest and more collapsible, while in the former the airway obstructed from mucus are the proximal ones¹¹. Besides, in asthmatic patients the airways are stiffer than in COPD patients; so, while airway resistance is higher than in COPD, the dynamic collapse during exhalation may be lower¹¹. Therefore, in asthmatic patients there is a higher risk of increasing air trapping by ventilating the patient with external-PEEP without knowing his auto-PEEP¹¹. This observation seems to be confirmed by some pathophysiologic studies and explains why the authors recommend to ventilate asthmatic patients with zero-PEEP^{11,12,13}.

From a clinical point of view asthma exacerbations may be divided as follows:

- mild: the patient can walk, lie down and speaks almost normally; he may be agitated and respiratory rate is < 30/min¹⁴;
- moderate: the patient can not lie down, can say just one sentence; he is agitated, respiratory rate is mildly increased but < 30/min¹⁴;
- severe: the patient sits up and leans his arms on the table, he is able to speak only a few words, is agitated and respiratory rate is severely increased (> 30/min). When the patient became confuse or disoriented, cardiac arrest is oncoming¹⁴.

In status asthmaticus, death follows asphyxia due to worsening respiratory distress². This is caused by air trapping and decreased ventilation that are followed by hypoxia, hypercapnia and acidosis². Often, in adults, viral upper airways infection are triggers for asthma exacerbations; however, other known triggers are psychosocial stress, exercise, and allergens².

Medical treatment of severe asthma and status asthmaticus is an important challenge for emergency physicians because therapy depends on the patient and on the degree of airflow obstruction. Asthma management includes²:

- O₂-therapy, that should be administered by any means until reaching pO₂ > 60 mmHg and SpO₂ 92%; high O₂ flux may be detrimental in hypercapnic patients².
- Bronchodilators, that acts on bronchial smooth muscle reducing bronchial obstruction²:

1. beta-agonists (mainly short-acting inhaled, like salbutamol); they should be administered by pressurized metered-dose inhalers with spacer; as an alternative, they can be administered by nebulization in O₂ 6-8 l/min. Oral or iv way of administration are not more effective, while they increase the risk of side effects (mostly arrhythmic). In severe asthma exacerbation, beta-agonists therapy should be repeated (2.5-5 mg per dose) every 10-20 min²;
 2. anticholinergics. The most effective is inhaled ipratropium bromide administered 80 mcg per dose by means of pressurized metered-dose inhalers with spacer. It can be repeated every 10 min².
- Corticosteroids, that act reducing airway inflammation and should be administered by 2 different ways²:
 1. systemic corticosteroids, may be administered orally or iv; the recommended dose is 40-60 mg prednisone or methylprednisolone². Probably, higher dose (> 160 mg methylprednisolone) are equally effective than lower doses²;
 2. inhaled corticosteroids, that seems to increase bronchodilator's effects².
 - Theophylline. As monotherapy, theophylline is inferior to beta-agonists; however, it can give an additional bronchodilator effect in association to beta-agonists. High incidence of side effects (like tachyarrhythmias) means that it may be useful only in severe asthma. Recommended loading dose is 6 mg/kg iv in 30 minutes followed by 0.5/kg/h until reaching theophylline blood levels 8-12 mcg/ml².
 - Magnesium sulphate: a safe and cheap medication with some bronchodilator effect. However, 3 recent meta-analysis did not confirm its clinical effectiveness^{2,16,17,18}.
 - Helium. When bronchial obstruction increases, airway flow becomes turbulent, so increasing airway resistance. Replacing nitrogen with helium (that is more viscous but equally inert) can reduce airway flow turbulence, so decreasing airway resistance. The benefits of heliox (helium + oxygen) are lost when large amounts of supplemental oxygen are introduced into the heliox breathing circuit (FiO₂ > 30% needed to maintain pO₂ > 60 mmHg)².
 - Other therapies (leukotriene antagonists, antibiotics) are not effective per se but may be useful in some selected case².

Theoretically, COPD and asthma should respond to non-invasive ventilation in the same way. However, while in COPD the efficacy of non-invasive ventilation is indisputable, there is not yet an agreement on using non-invasive ventilation in asthma.

In fact, some studies demonstrated that NIV can reduce the need for endotracheal intubation¹. In a study carried out in 2003, 30 patients were randomized in 2 groups: 15 treated with only conventional therapy, 15 treated with conventional therapy and NIV⁷. After 3 h both groups showed improve-

ment in lung function tests (FEV1, FVC, PEF) and BGA parameters, and decreasing in respiratory rate⁷. However, these parameters improve more significantly in patients treated with non-invasive ventilation⁷.

In another study, 36 patients admitted to an emergency department were randomized to 3 treatment arms: medical therapy + nebulization, and 2 treatment groups with medical therapy + nebulization + NIV¹⁵. In the 2 NIV groups, inspiratory pressure was the same, while expiratory pressure was different¹⁵. The authors of this study noticed that only the group with lower expiratory pressure showed significant clinical improvement¹⁵.

Another observational uncontrolled study showed an improvement of BGA parameters, heart and respiratory rate after NIV in patient with severe asthma exacerbations⁸. We can find the same results in a study on pediatric patients⁹. These studies suggest that in selected patients NIV may be useful as respiratory support for severe asthma. However, high power studies are lacking and in a Cochrane meta-analysis in 2005 just 1 of the 11 published studies satisfied inclusion criteria^{7,10}.

We report a case of a patient admitted for a severe asthma exacerbation, successfully treated with optimized medical therapy and NIV (zero-PEEP + pressure support). Even if anecdotal, it is not the first described in literature, because some authors described similar cases and some think that NIV may be effective in these patients^{6,7,8}. Some studies agree with our hypothesis, but they are small-sized and with low statistical power¹⁵. If these data were confirmed, NIV could prevent endotracheal intubation almost in some selected patient, preventing ICU hospitalization and so decreasing morbidity and costs.

Despite that, it is not yet established if NIV could worsen dynamic hyperinflation. Besides, the higher airway resistance of asthmatic patient could make NIV difficult, forcing the physician to increase pressure support, so increasing also air losses and risk of barotrauma. Because of this point of uncertainty, and because of lacking evidence, NIV is not routinely recommended in severe asthma exacerbations; however, the guidelines do not advise against its use^{2,14}. So, we can conclude that further studies are needed to clarify the role of non-invasive ventilation in asthmatic patients, patients selection criteria and timing compared to invasive ventilation.

ABSTRACT

Asthma is a chronic inflammatory disease affecting small airways, associated with hyperresponsiveness, reversible airflow-limitation and respiratory symptoms. During exacerbations, the symptoms severity may vary from mild dyspnea to fatal status asthmaticus. Non-invasive ventilation is a respiratory support method that in COPD has been used successfully in the last

References

1. Caples SM, Gay PC. Non invasive positive pressure ventilation in the intensive care unit: a concise review. *Crit Care Med* 2005; 33: 2651-2658.
2. Rodrigo GJ, Rodrigo C, Hall JB. Acute asthma in adults – a review. *Chest* 2004; 125; 1081-1102.
3. Brochard L, Mancebo J, Wysocki M *et al.* Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. *N Engl J Med* 1995; 333: 817-822.
4. Plant PK, Owen JL, Elliott MW. Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomised controlled trial. *Lancet* 2000; 355: 1931-1935.
5. Keenan SP, Sinuff T, Cook DJ *et al.* Which patients with acute exacerbation of chronic obstructive pulmonary disease benefit from noninvasive positive-pressure ventilation? A systematic review of the literature. *Ann Intern Med* 2003; 138: 861-870.
6. Ram FS, Picot J, Lightowler J *et al.* Noninvasive positive pressure ventilation for treatment of respiratory failure due to exacerbations of chronic obstructive pulmonary disease. *Cochrane Database Syst Rev* 2004; 1: CD004104.
7. Soroksky A, Stav D Shpirer I. A pilot prospective, randomized, placebo-controlled trial of bilevel positive airway pressure in acute asthmatic attack. *Chest* 2003; 123: 1018-1025.
8. Meduri GU, Cook TR, Turner RE *et al.* Non-invasive positive pressure ventilation in status asthmaticus. *Chest* 1996; 110: 767-774.
9. Thill PJ, McGuire JK, Baden HP *et al.* Noninvasive positive-pressure ventilation in children with lower airway obstruction. *Pediatr Crit Care Med* 2004; 5: 337- 342.
10. Ram FS, Wellington S, Rowe BH, Wedzicha JA. Non-invasive positive pressure ventilation for treatment of respiratory failure due to severe acute exacerbation of asthma. *Cochrane Database Syst Rev* 2005; 20(3): CD004360.
11. Medoff BD. Invasive and noninvasive ventilation in patients with asthma. *Respir Care* 2008; 53(6): 740-748.
12. Ranieri VM, Grasso S, Fiore T, Giuliani R. Auto-positive end-expiratory pressure and dynamic hyperinflation. *Clin Chest Med* 1996; 17(3): 379-394.
13. Tuxen DV. Detrimental effects of positive end-expiratory pressure during controlled mechanical ventilation of patients with severe airflow obstruction. *Am Rev Respir Dis* 1989; 140(1): 5-9.
14. Global Initiative for Asthma. *A pocket guide for physicians and nurses, updated 2009 guidelines.* <http://www.ginasthma.org>.
15. Brandao DC, Lima VM, Filho VG *et al.* Reversal of bronchial obstruction with bi-level positive airway pressure and nebulization in patients with acute asthma. *J Asthma* 2009; 46: 356-361.
16. Bourdon C, Camargo C, Bretzlaff J *et al.* Intravenous magnesium sulfate treatment for acute asthma in the emergency department: a systematic review of the literature. *Ann Emerg Med* 1999; 36: 181-190.
17. Koepsell T, Alter H, Hilty W. Intravenous magnesium as an adjuvant in acute bronchospasm: a meta-analysis. *Ann Emerg Med* 1999; 36: 191-197.
18. Rodrigo G, Rodrigo C, Burschtin O. Efficacy of magnesium sulfate in acute adult asthma: a meta-analysis of randomized trials. *Am J Emerg Med* 2000; 18: 216-221.

20 years; there is an increasingly interest about using non-invasive ventilation also in asthmatic patients. However, its role in status asthmaticus has not been yet established. In this article we report a case of a patient successfully treated with non-invasive ventilation and we also review the literature about non-invasive ventilation in acute asthma